Baxter Enters Bone Fusion Market Via $330 Million ApaTech Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Baxter will gain an immediate entry into the bone fusion market through its acquisition of Actifuse bone graft maker ApaTech for up to $330 million, including milestone payments, the firm says
You may also be interested in...
Baxter Expands Surgical Offerings Via $325 Mil. Synovis Acquisition
Deal adds soft tissue repair products including Veritas collagen matrix implants and Coupler devices for joining small diameter vessels.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover Baxter's acquisition of Apatech, the growth in biomarker-based tests in oncology, the CREST trial's positive results for carotid stenting, and new directions from FDA on how to plan pre-approval trials for novel cardiovascular combination products.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover Baxter's acquisition of Apatech, the growth in biomarker-based tests in oncology, the CREST trial's positive results for carotid stenting, and new directions from FDA on how to plan pre-approval trials for novel cardiovascular combination products.